Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease

Blood (2024) 143 (1): 21–31.

https://doi.org/10.1182/blood.2023020250

Published: 2024

Includes: Supplemental data

Journal Articles

Rational Modification of Human Gut Microbiome and Metabolites By Dietary Resistant Starch in Allogeneic Hematopoietic Stem Cell Transplantation: A Feasibility Study

Mary Mansour Riwes, Jonathan Louis Golob, John M. Magenau, Costas Lyssiotis, Mengrou Shan, Gregory Dick, Thomas Braun, Thomas M Schmidt, Attaphol Pawarode, Sarah Anand, Monalisa Ghosh, John Maciejewski, Darren King, Sung W. Choi, Gregory Yanik, Marcus Johannes Geer, Ethan Hillman, Muneesh Tewari, Pavan Reddy

Blood (2023) 142 (Supplement 1): 2190.

https://doi.org/10.1182/blood-2023-181260

Published: 2023

Journal Articles

Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome

Gregory A Yanik, David Frame, Gianni Bruno Scappaticci, Mary Maliarik, Steven W Pipe, Thomas Braun, Thomas Sisson, Paul G. Richardson, Daniel A Lawrence, Vibha Lama

Blood (2021) 138 (Supplement 1): 3237.

https://doi.org/10.1182/blood-2021-151417

Published: 2021

Journal Articles

Rational Modification of Intestinal Microbiome and Metabolites after Allogeneic Hematopoietic Stem Cell Transplantation with Resistant Starch: A Pilot Study

Mary Mansour Riwes, DO, Alexander Schmidt, Thomas Braun, John M. Magenau, MD, Attaphol Pawarode, Brian Parkin, Sarah Anand, MD, Monalisa Ghosh, John Maciejewski, Darren King, Muneesh Tewari, Sung W. Choi, Gregory A. Yanik, Kristi Maccready, Thomas Schmidt, Pavan Reddy

Blood (2019) 134 (Supplement_1): 3276.

https://doi.org/10.1182/blood-2019-131216

Published: 2019

Journal Articles

α 1 -Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease

John M. Magenau, Steven C. Goldstein, Dan Peltier, Robert J. Soiffer, Thomas Braun, Attaphol Pawarode, Mary M. Riwes, Maggi Kennel, Joseph H. Antin, Corey S. Cutler, Vincent T. Ho, Edwin P. Alyea, III, Brian L. Parkin, Gregory A. Yanik, Sung Won Choi, Eli C. Lewis, Charles A. Dinarello, John Koreth, Pavan Reddy

Blood (2018) 131 (12): 1372–1379.

https://doi.org/10.1182/blood-2017-11-815746

Published: 2018

Includes: Supplemental data

Journal Articles

Phase 2 Study of Pembrolizumab during Lymphodepleted State after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients

Attaphol Pawarode, MD, Anita D'Souza, MBBS, Marcelo C. Pasquini, MD, Bryon Johnson, PhD, Thomas Braun, PhD, Binod Dhakal, MBBS, Mehdi Hamadani, MD, John M. Magenau, MD, Nirav N Shah, MD, Mary Mansour Riwes, DO, Brian Parkin, MD, Pavan Reddy, MD, Parameswaran Hari, MD MRCP, MS

Blood (2017) 130 (Supplement 1): 339.

https://doi.org/10.1182/blood.V130.Suppl_1.339.339

Published: 2017

Journal Articles

Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT

Sung Won Choi, Thomas Braun, Israel Henig, Erin Gatza, John Magenau, Brian Parkin, Attaphol Pawarode, Mary Riwes, Greg Yanik, Charles A. Dinarello, Pavan Reddy

Blood (2017) 130 (15): 1760–1767.

https://doi.org/10.1182/blood-2017-06-790469

Published: 2017

Journal Articles

Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Attaphol Pawarode, MD, Steven Goldstein, MD, Daniel R. Couriel, MD, Thomas Braun, PhD, John M. Magenau, MD, Mary Mansour Riwes, DO, Brian Parkin, Vedran Radojcic, MD, David Frame, PharmD, Sung Choi, MD, James Connelly, MD, John E. Levine, MD MS, Gregory A. Yanik, MD, Pavan Reddy, MD

Blood (2015) 126 (23): 1907.

https://doi.org/10.1182/blood.V126.23.1907.1907

Published: 2015

Journal Articles

Plasma Concentration of ST2, the IL33 Receptor, At Initiation of Graft Versus Host Disease Therapy Predicts Day 28 Response and Day 180 Survival Post-Treatment

Mark T. Vander Lugt, M.D., Thomas Braun, PhD, James L.M. Ferrara, MD, DSc, Samir Hanash, M.D., Ph.D., John E. Levine, MD, MS, Chee-Hong Wang, Qing Zhang, Alice Chin, Andrew C. Harris, M.D., Sung W.J. Choi, M.D., Daniel Couriel, MD, Pavan Reddy, M.D., Sophie Paczesny, MD, PhD

Blood (2011) 118 (21): 152.

https://doi.org/10.1182/blood.V118.21.152.152

Published: 2011

Journal Articles

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies

Blood (2011) 118 (15): 4258–4264.

https://doi.org/10.1182/blood-2011-06-358010

Published: 2011

Includes: Supplemental data

Journal Articles

Three Biomarker Panel at Day 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease

Blood (2010) 116 (21): 675.

https://doi.org/10.1182/blood.V116.21.675.675

Published: 2010

Journal Articles

Standard Gvhd Prophylaxis Augmented with TNF-Inhibition in Alternative Donor HCT: Lower TNFR1 Levels Correlate with Better Outcomes.

Blood (2009) 114 (22): 43.

https://doi.org/10.1182/blood.V114.22.43.43

Published: 2009

Journal Articles

Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.

Shin Mineishi, MD, John Magenau, MD, Attaphol Pawarode, MD, Timothy Buck, Dawn Jones, RN, Koji Kato, MD, David Frame, Pharm.D, Lisa Kujawski, MD, Harry Paul Erba, MD, PhD, Yasser Khaled, MD, Edward M. Peres, MD, Oleg I. Krijanovski, PhD, MD, Pavan Reddy, MD, Carrie Kitko, MD, Sung Choi, MD, Gregory A. Yanik, MD, Thomas Braun, PhD, James L.M. Ferrara, MD, John E. Levine, MD

Blood (2008) 112 (11): 2150.

https://doi.org/10.1182/blood.V112.11.2150.2150

Published: 2008

Journal Articles

Bronchoscopic Evaluation of Pulmonary Complications in Patients Undergoing Reduced-Intensity Versus Full-Intensity Transplants.

Joseph Maslak, Daniel Kaul, MD, James Connelly, MD, Shin Mineishi, MD, John E. Levine, MD, Edward M. Peres, MD, Carrie Kitko, MD, Sung W. Choi, MD, Yasser Khaled, MD, Oleg I. Krijanovski, PhD, MD, Stefanie Digiandomenico, Eric White, MD, Thomas Braun, PhD, Pavan Reddy, MD, Attaphol Pawarode, MD, James L.M. Ferrara, MD, Gregory A. Yanik, MD

Blood (2008) 112 (11): 2163.

https://doi.org/10.1182/blood.V112.11.2163.2163

Published: 2008

Journal Articles

Elafin Is a Biomarker of Graft Versus Host Disease of the Skin

Sophie Paczesny, MD, PhD., John E. Levine, MD, Jason Hogan, PhD., Jeffrey Crawford, Thomas Braun, PhD, Hong Wang, PhD., Vitor Faca, PhD, Qing Zhang, Sharon Pitteri, PHD, Alice Chin, Sung Choi, MD, Carrie Kitko, MD, Oleg I. Krijanovski, PhD, MD, Pavan Reddy, MD, Shin Mineishi, MD, Joel Whitfield, Dawn Jones, RN, Samir Hanash, MD, PhD, James L.M. Ferrara, MD

Blood (2008) 112 (11): 716.

https://doi.org/10.1182/blood.V112.11.716.716

Published: 2008

Journal Articles

The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation

Gregory A. Yanik, Vincent T. Ho, John E. Levine, Eric S. White, Thomas Braun, Joseph H. Antin, Joel Whitfield, Joseph Custer, Dawn Jones, James L. M. Ferrara, Kenneth R. Cooke

Blood (2008) 112 (8): 3073–3081.

https://doi.org/10.1182/blood-2008-03-143412

Published: 2008

Journal Articles

Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival

Sung W. Choi, Carrie L. Kitko, Thomas Braun, Sophie Paczesny, Gregory Yanik, Shin Mineishi, Oleg Krijanovski, Dawn Jones, Joel Whitfield, Kenneth Cooke, Raymond J. Hutchinson, James L. M. Ferrara, John E. Levine

Blood (2008) 112 (4): 1539–1542.

https://doi.org/10.1182/blood-2008-02-138867

Published: 2008

Journal Articles

Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease

John E. Levine, Sophie Paczesny, Shin Mineishi, Thomas Braun, Sung W. Choi, Raymond J. Hutchinson, Dawn Jones, Yasser Khaled, Carrie L. Kitko, Daniel Bickley, Oleg Krijanovski, Pavan Reddy, Gregory Yanik, James L. M. Ferrara

Blood (2008) 111 (4): 2470–2475.

https://doi.org/10.1182/blood-2007-09-112987

Published: 2008

Includes: Supplemental data

Journal Articles

Etanercept Plus Methylprednisolone as Initial Therapy for Acute GVHD.

John E. Levine, MD, MS, Sophie Paczesny, MD, Shin Mineishi, MD, Thomas Braun, PhD, Sung W. Choi, MD, Raymond J. Hutchinson, MD, MS, Dawn Jones, RN, Yasser Khaled, MD, Carrie Kitko, MD, Oleg Krijanovski, MD, Pavan Reddy, MD, Gregory Yanik, MD, James L.M. Ferrara, MD

Blood (2007) 110 (11): 39.

https://doi.org/10.1182/blood.V110.11.39.39

Published: 2007

Journal Articles

A Four Protein Plasma Fingerprint of Acute Graft Versus Host Disease (GVHD) Predicts Long Term Survival.

Sophie Paczesny, MD, Sung Choi, MD, Thomas Braun, PhD, Carrie Kitko, MD, Krijanovski Oleg, MD, Shawn G. Clouthier, Angela Weyand, Dan Bickley, Dawn Jones, RN, Joel Whitfield, John E. Levine, MD, James L. Ferrara, MD

Blood (2007) 110 (11): 38.

https://doi.org/10.1182/blood.V110.11.38.38

Published: 2007

NARROW

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease

Rational Modification of Human Gut Microbiome and Metabolites By Dietary Resistant Starch in Allogeneic Hematopoietic Stem Cell Transplantation: A Feasibility Study

Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome

Rational Modification of Intestinal Microbiome and Metabolites after Allogeneic Hematopoietic Stem Cell Transplantation with Resistant Starch: A Pilot Study

α 1 -Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease

Phase 2 Study of Pembrolizumab during Lymphodepleted State after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Patients

Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT

Phase 1 Study of Carfilzomib for the Prevention of Relapse and Graft-Versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Plasma Concentration of ST2, the IL33 Receptor, At Initiation of Graft Versus Host Disease Therapy Predicts Day 28 Response and Day 180 Survival Post-Treatment

Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies

Three Biomarker Panel at Day 7 and 14 Can Predict Development of Grade II-IV Acute Graft-Versus-Host Disease

Standard Gvhd Prophylaxis Augmented with TNF-Inhibition in Alternative Donor HCT: Lower TNFR1 Levels Correlate with Better Outcomes.

Myeloablative Conditioning with Clofarabine and Busulfan X 4 (CloBu4) Is Well Tolerated, Facilitates Secure Engraftment, and Exhibits Significant Anti-Tumor Activity against Non-Remission Hematologic Malignancies Including AML.

Bronchoscopic Evaluation of Pulmonary Complications in Patients Undergoing Reduced-Intensity Versus Full-Intensity Transplants.

Elafin Is a Biomarker of Graft Versus Host Disease of the Skin

The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation

Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival

Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease

Etanercept Plus Methylprednisolone as Initial Therapy for Acute GVHD.

A Four Protein Plasma Fingerprint of Acute Graft Versus Host Disease (GVHD) Predicts Long Term Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only